Pharmafile Logo
Pharmafocus logo
Advanced Search

Regeneron

Showing 15 posts of 105 posts found.

shutterstock_274590824

Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron

February 26, 2019
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma

Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …

News
ipos0_l

Sanofi will pay Regeneron $582m in deal restructuring

January 7, 2019
Sales and Marketing Deals, Regeneron, Sanofi, biotech, pharma

French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal …

News
daphne_karydas

Allergan strengthens Finance Leadership Team with two appointments

December 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, MIT, Regeneron, appointment, pharma

The Dublin-headquartered multinational Allergan has appointed two experienced pharma investors to its Finance Leadership Team. The biopharmaceutical firm yesterday announced …

Appointment
ipos0_l

Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration

August 20, 2018
Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma

Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the …

News
800px-t_lymphocyte_16760076824

Regeneron Pharma and Bluebird bio announce immune cell collaboration

August 6, 2018
Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells

Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

News
praluentalirocumab_1211441

Sanofi/Regeneron forced to slash price in wake of slow sales

May 1, 2018
Research and Development, Sales and Marketing Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical, praluent

Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market …

News
handshake

Regeneron-Alnylam team up to treat NASH

March 22, 2018
Research and Development, Sales and Marketing Alnylam, Regeneron, biotech, drugs, nash, pharma, pharmaceutical

Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …

News
regeneron

Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy

March 20, 2018
Manufacturing and Production, Research and Development Eylea, Regeneron, diabetes, pharma

Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …

News
shutterstock_36423250

Sanofi and Regeneron reveal strong data and a price drop for Praluent

March 12, 2018
Research and Development, Sales and Marketing Regeneron, Sanofi, pharma, praluent

Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within …

News
regeneron

Appeal could throw spanner in the works for Regeneron’s Irish expansion

March 9, 2018
Manufacturing and Production, Medical Communications Ireland, Regeneron, pharma

Regeneron is facing a single man-sized obstacle in plans to expand operations at its campus in Limerick, Ireland with a …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

News
regeneron

Reports increasing of worrying side-effects with Regeneron’s Eylea

February 22, 2018
Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma

Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …

News
eylea-product-box-md

Regeneron forced to drop Eylea combo, advantage Novartis

November 27, 2017
Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical

Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …

News
regeneron

Regeneron injects $100 million and 300 new roles into Irish production facility

October 26, 2017
Manufacturing and Production Regeneron, Sanofi, manufacturing, pharma

Sanofi subsidiary Regeneron has announced its intention to expand its production plant in Limerick, Ireland – the largest scale bulk …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025